Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients
Objectives
In addition to motor symptoms, bladder dysfunction is a major clinical issue in patients with Parkinson disease (PD). Istradefylline is adenosine A2A receptor antagonist approved for PD patients with wearing-off symptoms. The aim of this study was to determine the long-term effects of istradefylline on lower urinary tract symptoms (LUTSs) in PD patients.
Methods
We enrolled 14 male PD patients. The mean age of patients was 73 years (61–77 years), the Hoehn-Yahr stage was 2 (2–3), and disease duration was 9 years (3–28 years). The effects of istradefylline (20 mg/d) on LUTSs in PD patients with motor c...
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study
Conclusions
This study indicates that atorvastatin could be an alternative for sodium valproate in migraine prophylaxis with comparable efficacy and fewer adverse effects. Multicenter studies with larger sample size are recommended. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia
The objective of this study was to compare the efficacy and safety of oral and transdermal rivastigmine for postural instability in patients with Parkinson disease dementia (PDD) who were candidates for a cholinesterase inhibitor. The primary outcome was the change in mean velocity of the center of pressure (CoP) after 6 months. Secondary outcomes included structural parameters of dynamic posturography, clinical rating scales, and adverse events requiring dose reduction.
Methods
Patients with PDD were randomized in a 1:1 ratio to oral or transdermal rivastigmine with target doses of 6 mg twice daily and 9.5 mg/10 cm2 da...
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Atomoxetine in the Treatment of Adolescent With Trichotillomania and Attention-Deficit/Hyperactivity Disorder
No abstract available (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Letters to the Editor Source Type: research
Treatment of Intermittent Explosive Disorder With Carbamazepine
No abstract available (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Letters to the Editor Source Type: research
A Well-Tolerated and Effective Antiepileptic Drug for Patients With Myasthenia Gravis at Last?
We report 2 cases of patients with MG who were safely treated with lacosamide. Evidence about antiepileptic drug treatment and adverse effects in MG is reviewed. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Allergy to Carbidopa
Conclusions
To the best of our knowledge, this is the first case report of an allergic reaction specific to carbidopa. Our case highlights the importance of identifying the source of a hypersensitivity drug response, whether it is caused by the active component or by the excipients. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Acute Onset of Abdominal Muscle Dyskinesia ("Belly Dancer Syndrome") From Quetiapine Exposure: A Case Report
Belly dancer syndrome, also called belly dance syndrome or belly dancer dyskinesia, is a kind of abdominal dyskinesia with painful sensation. Its etiology is still unclear and there are few studies reporting its association with antipsychotics. Quetiapine is an atypical antipsychotic that causes lower risk of extrapyramidal symptoms than typical antipsychotics. Here, we presented the first case of belly dancer syndrome in a 71-year-old woman with major depressive disorder after short-term use of quetiapine. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Camptocormia Induced by a Dopaminergic Agonist
This report demonstrates a case in which a dopaminergic agonist (DA) was implicated in the onset of camptocormia episodes in a non-PD patient who developed camptocormia after the start of DA treatment. Over a course of 8 years, the patient experienced intermittent camptocormia, which resulted in multiple falls. After cessation of the DA, the patient showed decreased camptocormia symptoms. This case report suggests that clinicians should consider the possibility of DA-induced camptocormia in patients with PD and non-PD patients receiving DA treatments, and serves to caution clinicians regarding the administration of DAs. (S...
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study
This study aimed to assess potential efficacy and safety of dextromethorphan/quinidine (DMQ) in prophylactic treatment of migraine in patients with multiple sclerosis (MS) with superimposed pseudobulbar affect (PBA).
Methods
Multiple sclerosis patients with superimposed PBA and comorbid migraine were enrolled into this open-label observational study at the University of Southern California Comprehensive MS Center. The baseline characteristics included, among other data, frequency and severity of acute migraine attacks and use of migraine relievers. The DMQ was used exclusively per its primary indication — PBA symptoms...
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Antipsychotic-Induced Pisa Syndrome: A 2-Year Follow-up Study
Conclusions
Pisa syndrome is an uncommon adverse event that can also be chronic or recurrent, especially in those with tardive onset. We should be aware of the risks in patients with the following predisposing factors: old age, chronic psychosis, long-term antipsychotic use, advanced drug-induced parkinsonism, and combined pharmacologic treatment. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center
Conclusions
Rituximab demonstrated good tolerability and efficacy in cases of both relapsing and progressive forms of MS and NMO. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
Conclusions
Concomitant dopaminergic agonist or MAO-B inhibitor use did not diminish the efficacy (improvement in “off” time and “on” time without troublesome dyskinesia) of ER CD-LD compared with IR CD-LD or CLE, whereas the improvement with concomitant amantadine failed to reach significance. Safety and tolerability were similar among the subgroups, and ER CD-LD did not increase troublesome dyskinesia. For patients on oral LD regimens and taking a dopaminergic agonist, and/or a MAO-B inhibitor, changing from an IR to an ER CD-LD formulation provides approximately an additional hour of “good” on time. (Sourc...
Source: Clinical Neuropharmacology - March 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Comment on: Selective Serotonin Reuptake Inhibitor–Induced Hyponatremia Clinical Implications and Therapeutic Alternatives
No abstract available (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - January 1, 2018 Category: Neurology Tags: Letter to the Editor Source Type: research
Carbamazepine Treatment of Hyperactivity and Intrusiveness in Dementia
We present a 70-year-old man with advanced Alzheimer disease and problematic disinhibited behaviors, including intrusiveness and Witzelsucht (disinhibited humor). These symptoms responded robustly to carbamazepine. Carbamazepine may be a useful adjunct in managing problematic behaviors in dementia, especially when those problems can be framed as behavioral disinhibition. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - January 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
